- Home
- SNES vs TCRT Comparison
SNES vs TCRT Comparison
Compare SNES & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNES
- TCRT
- Stock Information
- Founded
- SNES 2004
- TCRT 1998
- Country
- SNES United States
- TCRT United States
- Employees
- SNES N/A
- TCRT N/A
- Industry
- SNES Agricultural Chemicals
- TCRT Biotechnology: Pharmaceutical Preparations
- Sector
- SNES Industrials
- TCRT Health Care
- Exchange
- SNES Nasdaq
- TCRT Nasdaq
- Market Cap
- SNES 2.3M
- TCRT 2.6M
- IPO Year
- SNES 2016
- TCRT N/A
- Fundamental
- Price
- SNES $3.03
- TCRT $1.68
- Analyst Decision
- SNES Strong Buy
- TCRT
- Analyst Count
- SNES 1
- TCRT 0
- Target Price
- SNES $10.00
- TCRT N/A
- AVG Volume (30 Days)
- SNES 97.2K
- TCRT 12.3K
- Earning Date
- SNES 02-28-2025
- TCRT 03-31-2025
- Dividend Yield
- SNES N/A
- TCRT N/A
- EPS Growth
- SNES N/A
- TCRT N/A
- EPS
- SNES N/A
- TCRT N/A
- Revenue
- SNES $1,651,000.00
- TCRT $7,000.00
- Revenue This Year
- SNES $76.36
- TCRT N/A
- Revenue Next Year
- SNES $103.47
- TCRT N/A
- P/E Ratio
- SNES N/A
- TCRT N/A
- Revenue Growth
- SNES 38.16
- TCRT N/A
- 52 Week Low
- SNES $1.90
- TCRT $1.50
- 52 Week High
- SNES $9.80
- TCRT $26.00
- Technical
- Relative Strength Index (RSI)
- SNES 47.13
- TCRT 48.71
- Support Level
- SNES $3.18
- TCRT $1.59
- Resistance Level
- SNES $3.63
- TCRT $1.70
- Average True Range (ATR)
- SNES 0.42
- TCRT 0.09
- MACD
- SNES 0.00
- TCRT 0.01
- Stochastic Oscillator
- SNES 31.26
- TCRT 69.23
About SNES SenesTech Inc.
SenesTech Inc is a United States-based biotech platform and research company engaged in developing technology for managing animal pest populations through fertility control. The company provides its solutions to the animal market, commercial markets, and food markets. It currently has two product lines of fertility control products: ContraPest and Evolve.
About TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations.